Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)
NCT05566990Phase 3Completed
- Sponsor
- SK Plasma
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of polyvalent human immunoglobulin in immune thrombocytopenia (ITP), sponsored by SK Plasma. Primary endpoint: Responder rate (CR or R) at 28 days. Started Jul 2019; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05566990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566990.